Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Metastatic Castration-Resistant Prostate Cancer (mCRPC) × Metronidazole × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Colorectal Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Mouth Neoplasms 1 Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1 Lymphoma, B-Cell, Marginal Zone 1 Head and Neck Neoplasms 1 Adenocarcinoma 1

Interventions

sipuleucel-T 2 enzalutamide 2 gallium 68 PSMA-11 1 Vancomycin 1 Metronidazole 1 Docetaxel 1 Ciprofloxacin 1 Amoxicillin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06126731 2025-11-24

Combination Study of Antibiotics With Enzalutamide (PROMIZE)

Institute of Cancer Research, United Kingdom

Phase 1/2 Recruiting

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Data powered by HemOnc (CC BY 4.0) Colophon ⚡